Apr 14, 2007, 09.31 AM IST | Source: Moneycontrol.com

Alembic launching 7 new products

The Vadodara-based pharma company Alembic Ltd is set to launch several new products and expects to enter the $200-million formulations spectrum as a future growth strategy in the overseas market in the next couple of years.

Vadodara April 13

The Vadodara-based pharma company Alembic Ltd is set to launch several new products and expects to enter the $200-million formulations spectrum as a future growth strategy in the overseas market in the next couple of years.

The century-old Alembic with a basket of 200 products is now actively eyeing the $200-million spectrum in branded formulations business or API. It is also set to launch seven new products apart from the 24 it recently acquired from Dabur .

Plans are afoot to celebrate Alembic's centenary this year, Chairman and Managing Director, Mr Chirayu Amin, told Business Line here.

Besides, it is putting in place a new marketing strategy of its popular cough syrup Glycodin whose sales have shown a downward trend in the recent past.

contd on page 2...

Alembic stock price

On April 17, 2014, Alembic closed at Rs 18.45, up Rs 0.60, or 3.36 percent. The 52-week high of the share was Rs 21.45 and the 52-week low was Rs 8.50.


The company's trailing 12-month (TTM) EPS was at Rs 1.21 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 15.25. The latest book value of the company is Rs 7.71 per share. At current value, the price-to-book value of the company is 2.39.

1 2
Set email alert for

ADS BY GOOGLE

Buy & sell politicians on Power Play
- the political stock exchange

Price Update

Rahul Gandhi

576.23 -7.75 -1.33%

62344

Bought today

170682

Sold today

0.31%

User holding

video of the day

Chandra says satisfied with TCS' FY14, FY15 to be better

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.